BioNTech Declares New ADS Repurchase Program

(SeaPRwire) –   MAINZ, Germany, May 7, 2026 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the authorization of a new share repurchase program (the “Program”), under which it may buy back American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for up to $1.0 billion in total. The repurchases under the Program may occur through May 6, 2027. This authorization reflects BioNTech’s disciplined capital allocation strategy and strong financial position.

BioNTech intends to utilize the repurchased ADSs to meet routine business obligations. The Program aims to improve capital efficiency, support long-term value creation, and preserve financial flexibility, aligning with the Company’s goal of becoming a multi-product enterprise by 2030.

The start, timing, and total volume of ADS repurchases will depend on market conditions and may be conducted through periodic open market transactions, prioritizing price-efficient purchases to ensure prudent capital deployment. BioNTech plans to finance the Program using its current cash reserves.

“We remain confident in the Company’s long-term growth trajectory, and this share repurchase initiative aligns with our capital allocation framework and our dedication to sustainable value creation for shareholders,” said Ramón Zapata, Chief Financial Officer at BioNTech. “At the same time, our disciplined approach to capital deployment allows us to sustain the financial strength required to advance our innovative pipeline and pursue self-sustaining growth in the coming years.”

The Program is structured to comply with the safe harbor provisions of Rule 10b-18 and the affirmative defense under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

About BioNTech
BioNTech is a global next-generation biopharmaceutical company leading the development of novel investigational therapies for cancer and other serious diseases. In oncology, the Company is focused on transforming cancer treatment. Its mission is to create innovative medicines with pan-tumor or synergistic potential, addressing cancer from multiple perspectives across the entire disease spectrum—from early to advanced stages. The Company’s expanding late-stage oncology portfolio includes complementary modalities such as immunomodulators, antibody-drug conjugates, and mRNA-based cancer immunotherapies. BioNTech collaborates with a range of global and specialized pharmaceutical partners—including Bristol Myers Squibb, Duality Biologics, Genentech (a member of the Roche Group), Genmab, MediLink, OncoC4, and Pfizer—to combine expertise and resources, accelerating innovation and driving progress.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the Company’s intention to repurchase ADSs from time to time. Forward-looking statements may be identified by terms such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other similar expressions, though not all forward-looking statements include such language.
These forward-looking statements are based on BioNTech’s current expectations and beliefs about future events and are not guarantees or promises. Readers should not place undue reliance on these statements, as they involve known and unknown risks, uncertainties, and other factors—many beyond BioNTech’s control—that could cause actual outcomes to differ materially from those expressed or implied. These risks include, but are not limited to: fluctuations in the market price of the Company’s ADSs, general market conditions, and applicable securities regulations.

For a detailed discussion of these and other risks and uncertainties, please refer to the “Risk Factors” section in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings with the SEC, available at www.sec.gov. These forward-looking statements are valid only as of the date of this release. Except as required by law, BioNTech assumes no obligation to update or revise any forward-looking statements contained herein in light of new information, future events, or otherwise.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de